As previously reported, silencing FXYD2 expression in ovarian cancer cells resulted in the inhibition of Na+/K+-ATPase activity induced by increased sensitivity to cardiac glycosides, which are Na+/K+-ATPase inhibitors [35]. Here, FXYD2 is linked to ovarian cancer.